BuyersStrike!

It Was Dark Over Westphalia

Quick Take – Who's Grossly Overexaggerating Cytodyn's TAM Now? (CYDY)

Another day, another relentlessly "optimistic" piece of promotional garbage touting everyone's favorite Pink Sheet Reverse Merger coronacrapper, **Cytodyn (CYDY)**. Today it is this swill (https://seekingalpha.com/article/4356732-cytodyns-rude-interruption) which trumpeted an outlandish **TAM** (Total Addressable Market) figure that whipped up retail investors on both sides of the Atlantic this morning, before reality began to seep back in. How outlandish? See for yourselves:

> Cytodyn has identified possible revenues:
>
> - Coronavirus of $9 billion
> - HIV of up to $12 billion
> - Breast Cancer of $60 billion
>
> But this does not include other cancers, NASH, Multiple Sclerosis, and GvH (and Alzheimer's if it proves out). The numbers cited above come to $81 billion, if the company continues to operate on its own for five years, it may very well generate revenues of $100 billion, and multiplying it out,

Yes, **$81bn**, but that's not all, maybe even **$100bn!**

Now for the sobering reality. Cytodyn has exactly zero approved drugs to sell. Zero. After much difficulty they have submitted a BLA to the **FDA**, to hopefully get their wonder drug, **leronlimab**, approved in early **2021**. Guess that $81bn won't come this year, if at all.

But even if they get their drug approved, the actual TAM is far far smaller. For you see, dear reader, leronlimab is what is known as a **"CCR5 Entry Inhibitor"**, and one that must be delivered by IV or injection. There already is a another CCR5 entry inhibitor on the market, known generically as **maraviroc**, or by its brand name, **Selzentry**. Unlike the hyped unapproved bullshit from **Cytodyn**, maraviroc is a convenient pill, available today.

Contrary to anything the long list of promoters, or even **The Nadir**, might claim, leronlimab is not a new class of medication, it is not a breakthrough, it is just another entry in an existing segment.

And how large is the Total Addressable Market for **CCR5 Entry Inhibitors**? Currently maraviroc has **100%** of that market, and it was, for 2019 a paltry **$88mm** USD and **SHRINKING.**



Even if **leronlimab** magically captured 100% market share, **$88mm** is still only about **7/10ths of a percent** of the supposed **$12bn** HIV TAM. Good luck with that **$81bn**!

Oh, and coronavirus? If CCR5 entry inhibition had anything to do with Coronavirus, Doctors world-wide would already be using maraviroc. Surprise! **They aren't.**

Posted in Bad Directors, Bio-Dreck, Bucket Shops, Fail, Reverse Mergers on July 2, 2020 by BuyersStrike!. 2 Comments

2 comments

1. **hygrogroup** says:
   July 2, 2020 at 9:43 pm
   Perhaps you'll appreciate the latest CYDY pitch to the fanboys — https://insiderfinancial.com/cytodyn-otcmkts-cydy-bolts-higher-on-mexican-approval-chatter/180087/

   REPLY
2. **Dr. Zaius** says:
   July 6, 2020 at 10:53 pm
   You have strong medical opinions. In order to vet those opinions, I'm curious about your scientific background.

   [Background? Minister of Science and Chief Defender of the Faith, of course. All one needs to know is here. – **Editor**]

   REPLY